CSL Limited Annual Report 2021/22 8 CSL at a glance 40+ Countries of operations around theworld US$10.6 billion in annual revenue 30,000+ employees around the world 2,000+ R&D employees 330 Plasma collection centres across China, Europe and North America US$4.6 billion in R&D investments in the last 5 years to advance product pipeline Our businesses CSL Behring CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, haematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients’ lead full lives. CSL Behring operates one of the world’s largest plasma collection networks CSL Plasma. CSL Seqirus As one of the leading influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. CSL Seqirus operates state-of-the-art production facilities in the United States (US), the United Kingdom (UK) and Australia and utilises both egg-based and cell-based manufacturing technologies as well as a proprietary adjuvant. It has leading research and development (R&D) capabilities, a broad and differentiated product portfolio and commercial operations in more than 20 countries. 2 Our Company
RkJQdWJsaXNoZXIy MjE2NDg3